Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kathleen I Pritchard

Showing results (1-10 of 210) with videos related to

Pageof 21
Sort By:
The Lancet. Oncology|October 17, 2017
Extended adjuvant therapy: the role of subset analysesKathleen I Pritchard
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2002
Adjuvant therapy for premenopausal women with breast cancer: is it time for another paradigm shift?Kathleen I Pritchard
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|March 3, 2004
Is exercise effective in reducing the risk of breast cancer in postmenopausal women?Kathleen I Pritchard
Breast Cancer Research : BCR|January 9, 2009
Who should participate in clinical trials and who not? Can clinical trials be made more efficient and effective?Kathleen I Pritchard
Cancer Treatment and Research|July 14, 2009
Guidelines, consensus conferences and overviews (meta-analysis)Kathleen I Pritchard
European Journal of Cancer (Oxford, England : 1990)|June 29, 2007
Risk of chemotherapy induced menopause: more detailed data will lead to improved quality of lifeKathleen I Pritchard
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2009
Are HER2 and TOP2A useful as prognostic or predictive biomarkers for anthracycline-based adjuvant chemotherapy for breast cancer?Kathleen I Pritchard
Breast Cancer Research and Treatment|February 24, 2010
High levels of uPA and PAI-1 predict a good response to anthracyclinesKathleen I Pritchard
Breast (Edinburgh, Scotland)|December 17, 2019
Identifying research priorities in the treatment of patients with early breast cancer: from the patient perspectiveKathleen I Pritchard
The Oncologist|October 13, 2009
Commentary: anthracyclines in early-stage breast cancer: is it the end of an era?Kathleen I Pritchard
Pageof 21

Showing results (1-10 of 210) with videos related to

Sort By:
Pageof 21
The Lancet. Oncology|October 17, 2017
Extended adjuvant therapy: the role of subset analysesKathleen I Pritchard
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2002
Adjuvant therapy for premenopausal women with breast cancer: is it time for another paradigm shift?Kathleen I Pritchard
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|March 3, 2004
Is exercise effective in reducing the risk of breast cancer in postmenopausal women?Kathleen I Pritchard
Breast Cancer Research : BCR|January 9, 2009
Who should participate in clinical trials and who not? Can clinical trials be made more efficient and effective?Kathleen I Pritchard
Cancer Treatment and Research|July 14, 2009
Guidelines, consensus conferences and overviews (meta-analysis)Kathleen I Pritchard
European Journal of Cancer (Oxford, England : 1990)|June 29, 2007
Risk of chemotherapy induced menopause: more detailed data will lead to improved quality of lifeKathleen I Pritchard
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2009
Are HER2 and TOP2A useful as prognostic or predictive biomarkers for anthracycline-based adjuvant chemotherapy for breast cancer?Kathleen I Pritchard
Breast Cancer Research and Treatment|February 24, 2010
High levels of uPA and PAI-1 predict a good response to anthracyclinesKathleen I Pritchard
Breast (Edinburgh, Scotland)|December 17, 2019
Identifying research priorities in the treatment of patients with early breast cancer: from the patient perspectiveKathleen I Pritchard
The Oncologist|October 13, 2009
Commentary: anthracyclines in early-stage breast cancer: is it the end of an era?Kathleen I Pritchard
Pageof 21